Topical and transdermal delivery of hif-1 modulators to prevent and treat chronic wounds

Abstract

Compositions and methods are provided for the prevention and treatment of chronic wounds, including, without limitation, pressure ulcers and diabetic ulcers, by transdermal delivery of an agent that increases activity of HIF-1α in the wound.

What is claimed is: 
     
         1 . A transdermal patch comprising a film comprising a HIF-1α potentiator encapsulated in reverse micelles within a biodegradable polymer, and an impermeable backing membrane. 
     
     
         2 . The transdermal patch of  claim 1  wherein the HIF-1α potentiator comprises an iron chelator. 
     
     
         3 . The transdermal patch of  claim 2  wherein the iron chelator comprises DFO. 
     
     
         4 . The transdermal patch of  claim 3  wherein the DFO concentration is from at least 1% and not more than 20% as weight/weight percent of film. 
     
     
         5 . The transdermal patch of  claim 2  wherein the iron chelator comprises deferasirox. 
     
     
         6 . The transdermal patch of  claim 2  wherein the iron chelator comprises deferiprone. 
     
     
         7 . The transdermal patch of  claim 1  wherein the biodegradable polymer comprises an ethylcellulose matrix. 
     
     
         8 . The transdermal patch of  claim 1  further comprising PVP. 
     
     
         9 . The transdermal patch of  claim 8  wherein the PVP is present at a concentration of from about 5 wt % to about 25 weight %. 
     
     
         10 . The transdermal patch of  claim 1  wherein the HIF-1α potentiator is encapsulated in a reverse micelle with a non-ionic surfactant. 
     
     
         11 . The transdermal patch of  claim 10  wherein the non-ionic surfactant comprises a phospholipid.